From a future translational standpoint, combinatorial targeting of HIF2α and HIF1α may have a role in ccRCC treatment (perhaps particularly in a subset with high HIF1α protein expression/activity), and deserves exploration. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.